Source: EURLEX
Language: en
Format: md

201806080161931422018/C 221/206622016TC22120180625EN01ENINFO\_JUDICIAL20180503181811

Case T-662/16: Judgment of the General Court of 3 May 2018 — Gall Pharma v EUIPO — Pfizer (Styriagra) (EU trade mark — Opposition proceedings — Application for EU word mark Styriagra — Earlier EU word mark VIAGRA — Taking unfair advantage of the distinctive character or repute of the earlier mark — Article 8(5) of Regulation (EC) No 207/2009 (now Article 8(5) of Regulation (EU) 2017/1001))

[Top](#document1)

C2212018EN1810120180503EN0020181181

Judgment of the General Court of 3 May 2018 — Gall Pharma v EUIPO — Pfizer (Styriagra)

(Case T-662/16) (
[1](#t-C_2018221EN.01001801-E0001)
)

‛(EU trade mark — Opposition proceedings — Application for EU word mark Styriagra — Earlier EU word mark VIAGRA — Taking unfair advantage of the distinctive character or repute of the earlier mark — Article 8(5) of Regulation (EC) No 207/2009 (now Article 8(5) of Regulation (EU) 2017/1001))’

2018/C 221/20Language of the case: English

Parties

Applicant: Gall Pharma GmbH (Judenburg, Austria) (represented initially by: D. Reichelt and L. Figura, and subsequently by T. Schafft, lawyers)

Defendant: European Union Intellectual Property Office (represented by: D. Gája and D. Walicka, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard and J. Fuhrmann, lawyers)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 13 June 2016 (Case R 724/2015-5), relating to opposition proceedings between Pfizer and Gall Pharma.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |

| 2. | Orders Gall Pharma GmbH to pay the costs. |

---

(
[1](#c-C_2018221EN.01001801-E0001)
) [OJ C 441, 28.11.2016](./../../../legal-content/EN/AUTO/?uri=OJ:C:2016:441:TOC).

[Top](#document2)